Guardant Health Inc (GH) concluded trading on Wednesday at a closing price of $47.20, with 5.92 million shares of worth about $279.19 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 47.50% during that period and on January 22, 2025 the price saw a gain of about 4.59%. Currently the company’s common shares owned by public are about 123.16M shares, out of which, 117.73M shares are available for trading.
Stock saw a price change of 26.00% in past 5 days and over the past one month there was a price change of 45.86%. Year-to-date (YTD), GH shares are showing a performance of 54.50% which increased to 99.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.81 but also hit the highest price of $45.68 during that period. The average intraday trading volume for Guardant Health Inc shares is 1.97 million. The stock is currently trading 33.45% above its 20-day simple moving average (SMA20), while that difference is up 38.53% for SMA50 and it goes to 72.10% higher than SMA200.
Guardant Health Inc (NASDAQ: GH) currently have 123.16M outstanding shares and institutions hold larger chunk of about 103.01% of that.
The stock has a current market capitalization of $5.83B and its 3Y-monthly beta is at 1.32. It has posted earnings per share of -$4.24 in the same period. It has Quick Ratio of 5.85. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GH, volatility over the week remained 8.57% while standing at 6.23% over the month.
Analysts are in expectations that Guardant Health Inc (GH) stock would likely to be making an EPS of -0.52 in the current quarter, while forecast for next quarter EPS is -0.55 and it is -2.05 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.69 which is -0.45 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.64 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 22.07% while it is estimated to increase by 12.50% in next year. EPS is likely to grow at an annualized rate of -5.00% for next 5-years, compared to annual growth of -8.88% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Guggenheim on June 28, 2024 offering a Buy rating for the stock and assigned a target price of $36 to it. Coverage by Jefferies stated Guardant Health Inc (GH) stock as a Buy in their note to investors on June 03, 2024, suggesting a price target of $32 for the stock. Stock get a Peer perform rating from Wolfe Research on December 13, 2023.
